William B. Donnellan, MD

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations under investigation in acute leukemia.

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, reflects on some of the most pivotal FDA approvals in acute leukemia in the past year.

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations in light of newly FDA-approved agents in acute myeloid leukemia (AML).

William B. Donnellan, MD, investigator, Hematologic Malignancies, principal investigator, Sarah Cannon Research Institute, discusses preliminary results of the ENESTop study, which looked at treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase who were treated with second-line nilotinib (Tasigna).